JPRN-UMIN000016052已完成未知
Efficacy of IOP reduction and safety of Tapcom combination ophthalmic solution switched from Tapros 0.0015% and Timoptol XE 0.5% ophthalmic solution. - Efficacy of IOP reduction and safety of Tapcom combination ophthalmic solution switched from Tapros 0.0015% and Timoptol XE 0.5% ophthalmic solution.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •some corneal abnormality or other diseases which may interfere with accurate IOP measurement history of glaucoma surgery contraindicated to Beta blockers
研究者
相似试验
暂停
3 期
EPOCIM in benign prostatic hyperplasia.Benign prostatic hyperplasiaRPCEC00000092Center of Molecular Immunology(CIM)306
招募中
不适用
Efficacy IOP lowering and safety of Travoprost Ophthalmic Solution in Normal Tension Glaucoma patients.GlaucomaJPRN-UMIN000007026I.CHANGE study group100
已完成
不适用
Investigation of IOP reduction efficacy of Travoprost Ophthalmic Solution in patients with normal tension glaucomanormal tension glaucomaJPRN-UMIN000011621Alcon Japan Ltd34
已完成
不适用
A Comparative study of efficacy and safety of Tapcom combination ophthalmic solution and Xalacom combination eye drops.primary open angle glaucoma or ocular hypertensionJPRN-UMIN000023862Santen Pharmaceutical Co., Ltd.150
已完成
4 期
A Trial to study the effects of two drugs travoprost & brimonidine/timolol combination in patients with kanchbind (high pressure in eyes).CTRI/2011/11/002105nil70